# Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/long-term-real-world-safety-and-efficacy-of-teneligliptin-a-post-marketing/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Takashi Kadowaki,Masakazu Haneda,Hiroshi Ito,Kazuyo Sasaki,Miyuki Matsukawa,Yuka Yamada |
| Citations | 25 |
| DOI | 10.1007/s12325-019-01189-w |
| Fields | Medicine,Pharmacology, Toxicology and Pharmaceutics |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s12325-019-01189-w.pdf |
| OpenAlex ID | https://openalex.org/W2996392810 |
| PMID | 31873865 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Miyuki Matsukawa](https://scholariq.org/researchers/miyuki-matsukawa/)

## Paper journal

- [Advances in Therapy](https://scholariq.org/journals/advances-in-therapy/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pharmacovigilance and Adverse Drug Reactions](https://scholariq.org/topics/pharmacovigilance-and-adverse-drug-reactions/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.